Bioventus Inc.

NASDAQ:BVS

Medical - Devices

Healthcare
$10.62 +2.11%

+$0.18 today

Market cap
$727.20M
Beta
0.67
P/E (TTM)
20.6
EPS (TTM)
$0.42
52W Low $5.81High $11.25

Volume 0.70M

Average 0.56M

BVS EBITDA Margin

EBITDA as a percentage of revenue.

Bioventus Inc.NASDAQ: BVS

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin widens to 15.2%

EBITDA Margin was 15.2% in Q1 FY2026, up 2.3 pp from a year earlier. On a trailing-twelve-month basis it was 17.9%, up 11.6 pp year over year. Over 3 fiscal years it widened by 41.2 pp.

Context

  • EBITDA Margin widened in 3 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 4 analysts of 22.8% for the fiscal year ending Dec 2026, up from 17.5% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
15.2%-4.5 pp QoQ
Last fiscal yearDec 2025
17.5%+10.6 pp YoY
LTMMar 2026
17.9%+11.6 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+2.3 pp+0.9 pp-1.4 pp
1 year+10.6 pp+5.3 pp-5.3 pp
3 years+41.2 pp+7.0 pp-34.3 pp
5 years+3.6 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
17.5%
Year-over-year change
+10.6pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How BVS compares with its peers on the latest reported figures

  • BVS's LTM Mar 2026 EBITDA Margin of 17.9% is the 2nd highest of the 9 companies compared; the peer median is 8.5%.
  • Its year-over-year change of +11.6 pp is the 3rd highest of 9, against a peer median of +1.7 pp.
  • Over three fiscal years its change of +41.2 pp compares with a peer median of +1.9 pp.
BVS Competitors Peer median
EBITDA Margin for BVS and competitors
Company Period LTM level YoY 3-year change
SNNSmith & Nephew plcFY202521.7% -1.3 pp-0.4 pp
BVSBioventus Inc.LTM Mar 202617.9% +11.6 pp+41.2 pp
MDXGMiMedx Group, Inc.LTM Mar 202614.7% -3.3 pp+23.8 pp
OFIXOrthofix Medical Inc.LTM Mar 202611.5% +13.4 pp-6.1 pp
XTNTXtant Medical Holdings, Inc.LTM Mar 20269.7% +12.3 pp+21.2 pp
ORGOOrganogenesis Holdings Inc.LTM Mar 20267.3% +8.1 pp+4.2 pp
ANIKAnika Therapeutics, Inc.LTM Mar 2026-4.0% -3.6 pp-19.7 pp
IARTIntegra LifeSciences Holdings CorporationLTM Mar 2026-17.6% -28.7 pp-44.6 pp
TELATELA Bio, Inc.LTM Jun 2026-41.4% +4.7 pp+54.0 pp
Peer median (excluding BVS) 8.5%+1.7 pp+1.9 pp

Competitors are the stored peer set for BVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue430.9M512.12M512.35M573.28M568.09M
Cost of Revenue128.19M181.04M184.15M185.05M185.66M
Gross Profit302.71M331.08M328.19M388.23M382.43M
Gross Margin70.3%64.6%64.1%67.7%67.3%
Research & Development19.04M23.85M13.45M13.64M12.11M
Selling, General & Admin254.25M332.13M303.88M327.09M311.77M
Operating Expenses290.65M498.31M409.92M400.21M323.88M
Depreciation & Amortization34.88M55.4M57.37M49.56M47.01M
EBITDA45.48M(121.61M)(23.07M)39.22M99.21M
EBITDA Margin10.6%-23.7%-4.5%6.8%17.5%
Operating Income12.06M(167.23M)(81.73M)(11.98M)58.55M
Operating Margin2.8%-32.7%-16.0%-2.1%10.3%
Interest Income00000
Interest Expense1.11M12.02M40.68M38.79M26.49M
Other Income / Expenses(2.57M)(21.79M)(39.39M)(37.15M)(32.84M)
Income Before Tax9.49M(189.03M)(121.11M)(49.13M)25.71M
Pre-Tax Margin2.2%-36.9%-23.6%-8.6%4.5%
Income Tax Expense(1.97M)(44.37M)85K(5.29M)(1.57M)
Net Income19.38M(158.7M)(156.23M)(33.54M)22.73M
Net Margin4.5%-31.0%-30.5%-5.9%4.0%
EPS (Basic)(0.15)(2.59)(2.49)(0.52)0.34
EPS (Diluted)(0.15)(2.59)(2.49)(0.52)0.33
Weighted Avg Shares45.47M61.39M62.65M65.36M66.62M
Weighted Avg Shares (Diluted)45.47M61.39M62.65M65.36M68.91M

Bioventus Inc.

NASDAQ:BVS

Intrinsic Alpha fair value

Locked

Current Price

$10.62

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.